Efficacy of intravenous infusion of doripenem

Clinical Infectious Diseases

Volumn 49, Issue SUPPL. 1, 2009, Pages

  Restrepo, Marcos I ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EAR INFECTION; ENDOCARDITIS; EYE INFECTION; GYNECOLOGIC INFECTION; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; INTUBATION; LOWER RESPIRATORY TRACT INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; NOSE INFECTION; NOSOCOMIAL PNEUMONIA; PHARYNGITIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; REVIEW; SEPSIS; SKIN INFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

CARBAPENEMS; CROSS INFECTION; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 67749088182     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599812     Document Type: Review

References (21)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
2. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
3. Mehta RM, Niederman MS. Nosocomial pneumonia in the intensive care unit: controversies and dilemmas. J Intensive Care Med 2003; 18: 175-188 (Pubitemid 44526578)
4. Craven DE, Steger KA. Epidemiology of nosocomial pneumonia: new perspectives on an old disease. Chest 1995; 108:1S-16S.
5. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474 (Pubitemid 29083057)
6. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22:387-394 (Pubitemid 26174308)
7. Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117:1434-1442 (Pubitemid 30321602)
8. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31: S131-8.
9. Boucher H, Talbot G, Bradley J, et al. Bad bugs no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
10. Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14:413-420
11. Rahal J. Antimicrobial resistance and therapeutic options against gramnegative pathogens. Clin Infect Dis 2009; 49(Suppl 1):S4-10 (in this supplement).
12. Keam SJ. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 2008; 68:2021-2205
13. Naber KG, Redman R, Kotey P, Llorens L, Kaniga K. Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis [poster P 833]. In: Program and abstracts of the 17th Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy (Munich, Germany). 2007.
14. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, non-inferiority study. Clin Ther 2008; 30:868-883 (Pubitemid 351799866)
15. Malafaia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections [poster L-1564b]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). 2006.
16. Rea-Neto A, Niederman M, Lobo S, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24:2113-2126
17. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089-1096
18. Johnson & Johnson Pharmaceutical Research & Development. A study of the safety and effectiveness of doripenem compared with imipenem in the treatment of patients with ventilator-associated pneumonia. Raritan, NJ: Johnson & Johnson Pharmaceutical Research & Development, June 2008. ClinicalTrials.gov identifier: NCT00589693. Available at: http: //www.clinicaltrials.gov/ct2/show/NCT00589693?termpdoripenem+ AND+imipenem&rankp1. Accessed 22 July 2008.
19. Gilbert D. The truth, if it exists, is in the details. Crit CareMed 2008;36: 1368-1369
20. Chastre J, Jiang J, Kaniga K, Friedland I. Efficacy of doripenem against Pseudomonas aeruginosa in nosocomial pneumonia, including ventilator-associated pneumonia [poster P 556]. In: Program and abstracts of the 18th European Congress of Clinical Microbiology and Infectious Diseases (Barcelona, Spain). 2008.
21. Solomkin JS, Umeh O, Jiang J, Kaniga K, Friedland I. Doripenem versus meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections [poster L-487]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.